Bharat Immunolog Stock Price Today (NSE: 524663)

Bharat Immunolog

17.55+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Bharat Immunolog Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Bharat Immunolog share price today is 17.55, up +0.00% on NSE/BSE as of 22 June 2026. Bharat Immunolog (524663) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 86.92 (Cr). The 52-week high for 524663 share price is 24.75 and the 52-week low is 14.10. The company has a Return on Equity (ROE) of -17.67% and a debt-to-equity ratio of 0.94.

Bharat Immunolog Share Price Chart — NSE/BSE Historical Performance

No data
High
20.24
Low
16.25
Volume
36.2K
Change
-0.57%

Bharat Immunolog share price chart: -0.57% return over the past month. 52-week high ₹24.75, 52-week low ₹14.10.

Bharat Immunolog — Last 10 Trading Days

DateOpenHighLowCloseVolume
17.5617.9517.3517.559.75K (Cr)
17.6517.9517.3017.5619.39K (Cr)
17.5417.9017.3417.7328.10K (Cr)
17.4017.4917.1117.3411.35K (Cr)
17.5017.8017.1017.3914.37K (Cr)
17.4917.6517.2617.559.09K (Cr)
17.2417.6017.1517.5011.17K (Cr)
17.3517.4917.1217.1210.56K (Cr)
17.3017.7817.0517.2625.43K (Cr)
17.4017.7817.0217.474.38K (Cr)

Bharat Immunolog — Last 12 Months Price History

MonthOpenHighLowCloseChange
17.5617.9517.3517.55-0.06%
17.0020.2416.2517.56+3.29%
14.3718.5014.3717.24+19.97%
17.7919.4914.1014.25-19.90%
18.0621.8817.5018.00-0.33%
20.3020.5916.5517.95-11.58%
20.2022.6118.0020.07-0.64%
20.7921.3419.9020.25-2.60%
20.6122.0020.1020.35-1.26%
21.3023.1320.2220.84-2.16%
22.3023.1920.8521.54-3.41%
23.8024.3022.0122.30-6.30%

Returns & Performance

Poor

Return on Equity (ROE)

-17.67%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-9.27%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-17.84%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Bharat Immunolog Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

59.25%

% shares held by company founders/management

FII Holding

N/A

% shares held by foreign institutional investors

DII Holding

N/A

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-59.74%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-100.00%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

5.09%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.94x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-2.26x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-17.50 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Bharat Immunolog Fundamental Analysis & Valuation Benchmarking

Educational evaluation of 524663 across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Balanced Promoter Holding (59.25%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

8 factors identified

Below-Average Return on Equity (-17.67%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-9.27%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-17.84%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Profit Decline Concern (-59.74%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-100.00%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Weak Interest Coverage (-2.26x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-17.50 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Bharat Immunolog vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Bharat Immunolog with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
7/100
18
₹86.92
-17.67%
Poor
-9.27%
Poor
0.9
Good
5.09%
Good
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Bharat Immunolog Quarterly Performance

Latest quarterly metrics for 524663 — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-100.00%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-59.74%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

5.09%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Bharat Immunolog Technical Indicators

SMA 50, SMA 200, RSI and volume signals for 524663 — calculated from daily price history

50RSI 14
Neutral — RSI 50

Momentum is balanced — neither overbought nor oversold.

SMA 50
17
▲ Price above SMA 50 — Short-term bullish
SMA 200
19
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
36K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Bharat Immunolog Financial Statements

Annual income statement, balance sheet and cash flow for Bharat Immunolog (524663) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Bharat Immunolog

About 524663 (Bharat Immunolog)

Bharat Immunolog (524663) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current... market capitalisation of ₹86.92 (Cr). Bharat Immunolog has delivered a Return on Equity (ROE) of -17.67% and a ROCE of -9.27%. The debt-to-equity ratio stands at 0.94, reflecting the company's capital structure. Investors tracking 524663 share price can monitor key metrics including P/E ratio, promoter holding of 59.25%, and quarterly earnings growth.

Company Details

Symbol:524663
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:N/A

524663 Share Price: Frequently Asked Questions

What is the current share price of Bharat Immunolog?

Bharat Immunolog (524663) trades at ₹17.55 on BSE. Market cap ₹86.92 (Cr). Educational data only.

What is the P/E ratio of Bharat Immunolog?

Bharat Immunolog has a P/E of N/Ax vs industry average 31.77x.

What is the Bull Run score for Bharat Immunolog?

Bharat Immunolog has a Bull Run score of 7/100 based on 25+ financial parameters.

Does Bharat Immunolog pay dividends?

Bharat Immunolog has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Bharat Immunolog?

Bharat Immunolog has ROE of -17.67%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Bharat Immunolog?

Bharat Immunolog has debt-to-equity of 0.94.

Is Bharat Immunolog a good investment?

Bull Run gives Bharat Immunolog a score of 7/100. This is not investment advice — consult a SEBI-registered advisor.